Cytokinetics, Incorporated (CYTK) Bundle
Who Invests in Cytokinetics, Incorporated (CYTK) and Why?
Investor Profile Analysis for Biotechnology Company
As of Q4 2023, the investor landscape reveals specific investment characteristics:
| Investor Category | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.7% | 134,562,000 |
| Mutual Funds | 42.3% | 63,450,000 |
| Hedge Funds | 22.4% | 33,600,000 |
| Retail Investors | 10.3% | 15,450,000 |
Key Investor Motivations
- Market Capitalization: $3.82 billion
- Annual Revenue Growth: 37.6%
- Research Pipeline Potential
- Innovative Therapeutic Development
Investment Strategies
Dominant investment approaches include:
- Long-term Growth Positioning
- Biotechnology Sector Allocation
- Research-Driven Investment
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Holdings | 68.5% |
| Short-Term Trading | 19.3% |
| Value Investing | 12.2% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group | 22,345,000 | 14.8% |
| BlackRock | 18,675,000 | 12.4% |
| Fidelity Management | 15,230,000 | 10.1% |
Institutional Ownership and Major Shareholders of Cytokinetics, Incorporated (CYTK)
Investor Profile Analysis for Biotechnology Company
As of Q4 2023, the investor landscape reveals specific investment characteristics:
| Investor Category | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.7% | 134,562,000 |
| Mutual Funds | 42.3% | 63,450,000 |
| Hedge Funds | 22.4% | 33,600,000 |
| Retail Investors | 10.3% | 15,450,000 |
Key Investor Motivations
- Market Capitalization: $3.82 billion
- Annual Revenue Growth: 37.6%
- Research Pipeline Potential
- Innovative Therapeutic Development
Investment Strategies
Dominant investment approaches include:
- Long-term Growth Positioning
- Biotechnology Sector Allocation
- Research-Driven Investment
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Holdings | 68.5% |
| Short-Term Trading | 19.3% |
| Value Investing | 12.2% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group | 22,345,000 | 14.8% |
| BlackRock | 18,675,000 | 12.4% |
| Fidelity Management | 15,230,000 | 10.1% |
Key Investors and Their Influence on Cytokinetics, Incorporated (CYTK)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the company stands at 89.7%, representing a significant portion of total shares.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 24,567,890 | 16.3% |
| BlackRock Inc | 19,345,672 | 12.8% |
| Fidelity Management & Research | 15,678,234 | 10.4% |
Recent institutional investment trends reveal notable changes:
- Total institutional holdings increased by 7.2% in the last quarter
- Net institutional purchases reached $456.7 million
- Insider ownership accounts for 3.5% of total shares
Institutional investors have demonstrated significant confidence, with 62 institutions increasing their positions and 38 reducing their stakes during the most recent reporting period.
| Ownership Category | Percentage |
|---|---|
| Mutual Funds | 42.6% |
| Investment Advisors | 29.3% |
| Pension Funds | 17.8% |
Market Impact and Investor Sentiment of Cytokinetics, Incorporated (CYTK)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for the company reveals significant institutional involvement and strategic ownership patterns.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 8,456,721 | 12.3% |
| Vanguard Group Inc. | 7,234,512 | 10.5% |
| Fidelity Management & Research | 5,876,342 | 8.7% |
Investor Influence Dynamics
- Institutional investors hold 68.2% of total outstanding shares
- Insider ownership represents 4.5% of total shares
- Top 10 institutional investors control 45.6% of company stock
Recent Investor Movements
| Investor | Q4 2023 Transaction | Value |
|---|---|---|
| Wellington Management | Increased Position | $42.3 million |
| Goldman Sachs | New Position Established | $28.7 million |
Institutional investment indicates strong market confidence with $672 million total institutional investments as of December 2023.
Cytokinetics, Incorporated (CYTK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.